证券代码：300529 证券简称：健帆生物 公告编号：2025-032 债券代码：123117 债券简称：健帆转债 4、根据《会议规则》的相关规定，经表决通过的债券持有人会议决议对本 次可转换公司债券全体债券持有人（包括未参加会议或明示不同意见的债券持有 人）具有法律约束力。 健帆生物科技集团股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日 召开了第五届董事会第二十八次会议，审议通过了《关于召开"健帆转债"2025 年第一次债券持有人会议的议案》，董事会提议于 2025 年 5 月 9 日召开"健帆转 债"2025 年第一次债券持有人会议，现将本次债券持有人会议的有关事项通知 如下： 一、召开会议的基本情况 健帆生物科技集团股份有限公司 关于召开健帆转债 2025 年第一次债券持有人会议的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示 1、债权登记日：2025 年 4 月 29 日（星期二） 2、会议召开时间：2025 年 5 月 9 日（星期五）14:30 3、根据《健帆生物科技集团股份有限公司创业板向不特定对象发行可转换 ...

| 证券代码：300529 | 证券简称：健帆生物 | 公告编号：2025-031 | | --- | --- | --- | | 债券代码：123117 | 债券简称：健帆转债 | | 健帆生物科技集团股份有限公司 第五届董事会第二十八次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 健帆生物科技集团股份有限公司（以下简称"公司"）第五届董事会第二十 八次会议于 2025 年 4 月 23 日在公司会议室以现场会议及通讯表决的方式召开， 本次会议应出席董事 9 人，实际出席董事 9 人，符合《公司法》和公司章程的有 关规定。本次会议通知提前以电子邮件及电话通知等方式向全体董事送达。公司 董事长董凡先生召集和主持了本次会议，公司监事和高级管理人员列席了会议。 本次董事会的召开符合《公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 经与会董事认真讨论，审议并表决通过了以下议案： 1、 审议通过了《关于聘任可转债受托管理人的议案》 为了有效维护债券持有人享有的法定权利，依据《公司债券发行与交易管理 办法》第五十八条" ...

上 市 公 司 医药生物 2025 年 04 月 21 日 健帆生物 (300529) ——2024 年业绩高增，看好公司长期健康发展 报告原因：有业绩公布需要点评 买入（维持） | 市场数据： | 2025 年 04 月 18 日 | | --- | --- | | 收盘价（元） | 22.40 | | 一年内最高/最低（元） | 39.24/21.76 | | 市净率 | 5.2 | | 股息率%（分红/股价） | 1.79 | | 流通 A 股市值（百万元） | 11,479 | | 上证指数/深证成指 | 3,276.73/9,781.65 | | 注："股息率"以最近一年已公布分红计算 | | | 基础数据: | 2025 年 03 月 31 日 | | --- | --- | | 每股净资产（元） | 4.27 | | 资产负债率% | 37.85 | | 总股本/流通 A 股（百万） | 799/512 | | 流通 B 股/H 股（百万） | -/- | 一年内股价与大盘对比走势： 04-18 05-18 06-18 07-18 08-18 09-18 10-18 11-18 12-18 01 ...

Investment Rating - The report indicates a positive outlook for the weight loss drug sector within the pharmaceutical and biotechnology industry, suggesting potential acceleration in business development (BD) opportunities [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a slight decline of -0.36% from April 14 to April 18, underperforming compared to the Wind All A index (0.39%) and the CSI 300 index (0.59). The market showed a preference for defensive sectors, with chemical preparations (0.62%), traditional Chinese medicine (0.6%), and offline pharmacies (0.19%) showing minor gains, while blood products (-4.39%), other biological products (-1.78%), and vaccines (-1.49%) saw significant pullbacks [2][7]. - The GLP-1 receptor agonists are expected to catalyze growth in the weight loss drug sector. Notably, Eli Lilly announced positive results from the Phase III ACHIEVE-1 study for its oral drug Orforglipron, which is set to expand the application of GLP-1 drugs. This class of drugs is becoming a focal point for multinational corporations (MNCs) in the metabolic disease space, with domestic companies poised to benefit from rapid innovation and lower R&D costs [2][12]. Market Weekly Review - The pharmaceutical and biotechnology sector's performance from April 14 to April 18 showed a decline of -0.36%, with the market favoring defensive stocks. The top gainers included Shuangcheng Pharmaceutical (56.4%), Kangpeng Technology (56.3%), and Lifang Pharmaceutical (47.1%), while the largest losers were *ST Jiyuan (-50.7%), Hasanlian (-19.1%), and Changyao Holdings (-18.5%) [7][10]. Industry News and Key Company Announcements - On April 17, Eli Lilly announced that its oral GLP-1 receptor agonist Orforglipron achieved positive results in its Phase III study, showing significant reductions in A1C levels and weight loss compared to placebo [12]. - Pfizer terminated the development of its GLP-1 small molecule receptor agonist Danuglipron due to potential liver damage in trial participants [12]. - The report highlights several companies making strides in the industry, including the approval of new indications for Merck's Gardasil 9 HPV vaccine and the progress of various clinical trials for innovative drugs [13][14].

Investment Rating - The report maintains a positive outlook on the pharmaceutical sector, particularly on innovative drugs and their internationalization process, while suggesting a focus on blood products and scientific instruments in the short term [4][18]. Core Insights - The pharmaceutical sector has shown stable stock performance, with significant approvals for innovative drugs such as the IL-21/IL-23 dual antibody by Kangfang Biopharma and the successful phase 3 clinical trial results for Eli Lilly's orforglipron [1][2][18]. - The report emphasizes the resilience and growth potential of the pharmaceutical sector amidst changing external tariff environments, highlighting low geopolitical risks for innovative drugs and opportunities for domestic replacements in blood products and medical devices [4][18]. - The report suggests a continuous focus on innovative and semi-innovative drug companies, as well as potential recovery in the performance of generic drugs, chain pharmacies, and traditional Chinese medicine post-Q1 reports [4][20]. Summary by Sections Pharmaceutical Sector - Kangfang Biopharma's IL-21/IL-23 dual antibody has been approved for moderate to severe plaque psoriasis, marking a significant milestone as the first domestic drug of its kind [19]. - The approval of AstraZeneca's capivasertib for second-line breast cancer treatment further highlights the growing number of innovative drugs being approved in China [23][25]. - The report anticipates a surge in licensing transactions as Chinese innovative drug assets mature, leading to more predictable performance for pharmaceutical companies [2][25]. Biological Products - Eli Lilly's orforglipron has successfully completed phase 3 clinical trials, demonstrating superior A1C reduction compared to placebo, which positions it as a leading oral GLP-1 receptor agonist [26][29]. - The report encourages monitoring the progress of domestic GLP-1 small molecules, which are showing promising clinical results [33][34]. Medical Devices - Domestic companies are making significant strides in innovative research and development, with products like the LiqMagic peripheral vascular shockwave treatment system gaining traction in clinical applications [35][36]. - The report notes that the innovative technology in vascular treatment is expected to enhance patient outcomes and reduce procedural risks [35][36]. Investment Recommendations - The report recommends focusing on innovative and semi-innovative drug companies such as Kelun-Biotech, Kangfang Biopharma, and Huadong Medicine, as well as blood products and scientific instruments for potential domestic replacements [5][20]. - It also suggests paying attention to the recovery of generic drugs, chain pharmacies, and traditional Chinese medicine as the market stabilizes post-Q1 [4][20].

4月18日，深交所以"成长新启航·民企百舸竞中流"为主题，在上市大厅组织召开2024年度深市首场上市 公司集体业绩说明会。 会上，双林股份、健帆生物、万孚生物、信立泰作为深市民企代表向市场展示企业的最新发展成果，并 围绕科技创新、关税战、国际化、发展战略等方面，积极回应投资者的关切。 谈科技创新：积极拥抱AI新技术 创新是民营经济发展的核心动力。近年来，深市民营上市公司在研发投入、技术创新和专利积累方面持 续发力，凸显了其作为创新主体的领先地位。 健帆生物的主营业务集中在生物材料和高科技医疗器械的研发、生产及销售，尤其是在血液净化领域具 有显著的技术优势。据介绍，健帆生物将不断加强生产经营和内部管理，做好产能布局。并持续加强技 术创新与产品升级迭代，丰富血液灌流器产品线，提高公司产品结构的多样化。 在当今数字化时代，人工智能（AI）的发展速度令人瞩目。这一技术已深入众多行业，促进了产业的 转型升级，显著提高了生产效率。围绕这一热门话题，多家代表企业也在业绩说明会上进行了回应。 "公司与客户保持了紧密沟通，公司出口业务主要采用FOB交易方式，关税和运费由客户承担，公司已 经凭借竞争力和客户形成了生态链深入绑定。 ...

Group 1: Market Strategy and Product Development - The company is preparing for potential centralized procurement of blood purification consumables by enhancing production management and capacity layout, focusing on technological innovation and product diversification [1][3][4] - There are no current plans to reduce product prices, as the company aims to maintain a reasonable profit margin while expanding into new markets, particularly in severe liver diseases and critical conditions [1][2] Group 2: Fixed Asset Investment - Recent investments in fixed assets are directed towards high-value resin projects, medical device production, and automation improvements, which are expected to enhance scale and cost advantages [2][3] - The strategic decision to build fixed assets is aimed at ensuring product safety and increasing market share, thereby solidifying the company's leading position [2] Group 3: Shareholder Value and Market Confidence - The company's stock price has decreased by approximately 30% since the introduction of its market value management initiative, prompting discussions on potential share buybacks using part of the 2.1 billion yuan in financial assets [2][3] - The company has implemented various measures to boost investor confidence, including share repurchases, cash dividends, and equity incentive plans [2][3] Group 4: Research and Development - As of the report date, the company has 486 R&D personnel, accounting for 17.38% of total employees, indicating a strong commitment to research despite a recent reduction in R&D staff due to project completions [4][5] - The company is actively exploring new business areas related to metabolic diseases and cardiovascular health, collaborating with top hospitals for clinical research [5][6] Group 5: International Expansion - The company is focusing on internationalization by restructuring its overseas sales teams and engaging in cross-border research collaborations, with a notable project recognizing 17 award-winning topics across various medical fields [5][6] - A consensus report on blood adsorption therapy has been published, providing a high-level evidence base for international clinical applications [5][6]

证券代码：300529 证券简称：健帆生物 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 投资者关系活动记录表 编号：2025-001 | | □ □ 分析师会议 | 特定对象调研 | | --- | --- | --- | | 投资者关系 活动类别 | □ 业绩说明会 | □ 媒体采访 | | | □ 路演活动 | □ 新闻发布会 | | | □ √ 其他（线上会议） | 现场参观 | | 参与人员 | 华泰证券、西南证券、东北证券、国盛证券、国金证券、东吴证券、中信建投 证券、中信证券、国信证券、中邮证券、西部证券、南方基金、大成基金、博 | | | | 证券、华福证券、申万宏源证券、兴业证券、国联民生证券、国信证券、中泰 | | | | 时基金、上海人寿、招商基金、新华基金、中航基金、友邦人寿、红杉中国、 | | | | 华夏基金、广发基金、中银基金、景顺长城基金、IDG 资本、工银瑞信等七十 | | | | | 余位投资者 | | 时间 | 日 2025 | 年 月 4 16 | | 地点 | | 线上沟通 | | 上市公司接 | 董事长、总经理：董凡 | | | | 董事 ...

健帆生物 20250116 年同期高基数下，同比营业收入和净利润有所下降。一季度收入为 5.48 亿元， 同比下降 26%，主要原因是去年初公司将主营产品终端价格下调了 26%以价 换量，实现了显著的销量提升。今年一季度在此高基数上同比数据有所下降， 但环比增长 13.75%。经营性现金流量净额为 2.7 亿元，超过当期净利润 8,000 万元，现金流质量依然保持高水平。一季度毛利率为 80.7%，归母净利 率 34.6%，略高于去年全年的水平。 健帆生物在各个领域的主要亮点是什么？ 在营销领域，公司胜科产品覆盖全国 6,000 多家二级以上医院，基本覆盖可以 做透析的医院。胜科血液灌流器产品收入同比增长 57%，主要因为公司将 HA130 终端价格下降 26%，销售支数同比增长近 100%。Kha 系列覆盖 600 多家医院，24 年销售收入 1.46 亿，同比增长 188%。PA 灌流器已在 100 多 家医院使用。肝科领域覆盖 2000 多家医院，24 年度销售收入同比增长 77%。重症领域覆盖 1,800 多家医院，相应产品同比增长 52%。 公司的 CA 细胞因子吸附柱用于清除脓毒症患者体内白介素 ...

报名：首届全球眼科大会 | 参会须知 报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 合作伙伴征集：2025全球手术机器人大会 2025年4月16日， 健帆生物 发布了2024年年报。 # 财报数据 健帆生物2024年实现营业 收入26.77亿元 ，同比 增长39.27% 。归属于上市公司股东的净利润为8.20亿元，同比 增长87.91% 。扣除非经常性损益的净利润为 7.79亿元，同比 增长90.46% 。 业务核心驱动力 分红政策 公司2024年度权益分配预案为每10股派发现金红利8元（含税），合计派发现金红利6.19亿元，占净利润的比例为 75.53% 。 每股收益 ：基本每股收益为1.05元，同比 增长90.91% 。 经营活动现金流 ：经营活动产生的现金流量净额为10.51亿元，同比增长14.64%。 资产总额 ：截至2024年末，公司资产总额为53.83亿元，较上年末下降2.88%。 产品销售增长 ：公司血液灌流器及吸附器产品销售收入达到25.04亿元，同比增长59.58%，是推动营收增长的主要因素。 市场拓展与新产品推广 ：公司在肾病、肝病和危重症领域持续巩固市场领 ...